Program Information PreludeDx is a biotechnology company that provides a 7-gene genomic assay that helps patients and doctors understand the risk of recurrence in individual patients cancer in Stage 0 Breast Cancer (DCIS). The test gives patients a 10 year timeline on their risk of recurrence in invasive cancer both with and without radiation therapy, and rates their overall risk on a scale of 1-10. Our aim is to reduce the amount of patients that are being under or over treated under current DCIS treatment guidelines.